Results of radical prostatectomy in men with clinically localized prostate cancer. 1996

G S Gerber, and R A Thisted, and P T Scardino, and H G Frohmuller, and F H Schroeder, and D F Paulson, and A W Middleton, and D B Rukstalis, and J A Smith, and P F Schellhammer, and M Ohori, and G W Chodak
Section of Urology, Department of Surgery, University of Chicago (III) Pritzker School of Medicine, IL 60637, USA.

OBJECTIVE To assess the results of radical prostatectomy in men with early prostate cancer. METHODS Retrospective, nonrandomized, multi-institutional pooled analysis. METHODS Eight university medical centers in the United States and Europe. METHODS A total of 2758 men with stage Tl and T2 prostatic cancer. METHODS Disease-specific and metastasis-free survival rates. RESULTS Tumor grade was the most important preoperative factor in determining outcome. Disease-specific survival 10 years following surgery and associated 95% confidence intervals were 94% (range, 87%-98%), 80% (range, 74%-85%), and 77% (range, 65%-86%) for those men with grade 1, 2, and 3 tumors, respectively. Metastasis-free survival at 10 years was 87% (range, 78%-92%), 68% (range, 62%-73%), and 52% (range, 38%-64%) for patients with grade 1, 2, and 3 cancers, respectively. CONCLUSIONS Radical prostatectomy leads to high 10-year disease-specific survival rates in men with all tumor grades. However, caution is needed in comparing these results with similar studies of alternative treatment strategies, such as watchful waiting, due to the inherent potential biases in uncontrolled trials. Nevertheless, these results offer the best currently available estimates of 10-year outcome of radical prostatectomy in men with clinically localized prostate cancer and may be useful in counseling patients with early malignancy.

UI MeSH Term Description Entries
D008297 Male Males
D011468 Prostatectomy Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE). Prostatectomy, Retropubic,Prostatectomy, Suprapubic,Prostatectomies,Prostatectomies, Retropubic,Prostatectomies, Suprapubic,Retropubic Prostatectomies,Retropubic Prostatectomy,Suprapubic Prostatectomies,Suprapubic Prostatectomy
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D005060 Europe The continent north of AFRICA, west of ASIA and east of the ATLANTIC OCEAN. Northern Europe,Southern Europe,Western Europe
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D016016 Proportional Hazards Models Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time. Cox Model,Cox Proportional Hazards Model,Hazard Model,Hazards Model,Hazards Models,Models, Proportional Hazards,Proportional Hazard Model,Proportional Hazards Model,Cox Models,Cox Proportional Hazards Models,Hazard Models,Proportional Hazard Models,Hazard Model, Proportional,Hazard Models, Proportional,Hazards Model, Proportional,Hazards Models, Proportional,Model, Cox,Model, Hazard,Model, Hazards,Model, Proportional Hazard,Model, Proportional Hazards,Models, Cox,Models, Hazard,Models, Hazards,Models, Proportional Hazard
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses

Related Publications

G S Gerber, and R A Thisted, and P T Scardino, and H G Frohmuller, and F H Schroeder, and D F Paulson, and A W Middleton, and D B Rukstalis, and J A Smith, and P F Schellhammer, and M Ohori, and G W Chodak
December 1996, JAMA,
G S Gerber, and R A Thisted, and P T Scardino, and H G Frohmuller, and F H Schroeder, and D F Paulson, and A W Middleton, and D B Rukstalis, and J A Smith, and P F Schellhammer, and M Ohori, and G W Chodak
December 1996, JAMA,
G S Gerber, and R A Thisted, and P T Scardino, and H G Frohmuller, and F H Schroeder, and D F Paulson, and A W Middleton, and D B Rukstalis, and J A Smith, and P F Schellhammer, and M Ohori, and G W Chodak
June 2002, Current urology reports,
G S Gerber, and R A Thisted, and P T Scardino, and H G Frohmuller, and F H Schroeder, and D F Paulson, and A W Middleton, and D B Rukstalis, and J A Smith, and P F Schellhammer, and M Ohori, and G W Chodak
January 2014, European urology,
G S Gerber, and R A Thisted, and P T Scardino, and H G Frohmuller, and F H Schroeder, and D F Paulson, and A W Middleton, and D B Rukstalis, and J A Smith, and P F Schellhammer, and M Ohori, and G W Chodak
January 2001, Cancer control : journal of the Moffitt Cancer Center,
G S Gerber, and R A Thisted, and P T Scardino, and H G Frohmuller, and F H Schroeder, and D F Paulson, and A W Middleton, and D B Rukstalis, and J A Smith, and P F Schellhammer, and M Ohori, and G W Chodak
November 1994, The Canadian journal of oncology,
G S Gerber, and R A Thisted, and P T Scardino, and H G Frohmuller, and F H Schroeder, and D F Paulson, and A W Middleton, and D B Rukstalis, and J A Smith, and P F Schellhammer, and M Ohori, and G W Chodak
December 2005, Nature clinical practice. Oncology,
G S Gerber, and R A Thisted, and P T Scardino, and H G Frohmuller, and F H Schroeder, and D F Paulson, and A W Middleton, and D B Rukstalis, and J A Smith, and P F Schellhammer, and M Ohori, and G W Chodak
May 2002, Seminars in urologic oncology,
G S Gerber, and R A Thisted, and P T Scardino, and H G Frohmuller, and F H Schroeder, and D F Paulson, and A W Middleton, and D B Rukstalis, and J A Smith, and P F Schellhammer, and M Ohori, and G W Chodak
August 2011, The Journal of urology,
G S Gerber, and R A Thisted, and P T Scardino, and H G Frohmuller, and F H Schroeder, and D F Paulson, and A W Middleton, and D B Rukstalis, and J A Smith, and P F Schellhammer, and M Ohori, and G W Chodak
January 2009, International urology and nephrology,
Copied contents to your clipboard!